Link to the full source article

RSS feed source: Centers for Disease Control and Prevention--Office of Public Health Preparedness and Response

New data released today in CDC’s MMWR show that nirsevimab, a long-acting monoclonal antibody product, was highly effective in protecting infants from hospitalizations associated with respiratory syncytial virus (RSV).

Click this link to continue reading the article on the source website.